Molten Ventures Regulatory News (MVCT)

Molten Ventures VCT plc

("Molten", the "VCT" or the "Company")

Legal Entity Identifier: 2138003I9Q1QPDSQ9Z97

Hologic Inc. to acquire Endomagnetics for approx. $310m

Molten Ventures VCT plc (LSE: MVCT), a leading Venture Capital Trust investing in and developing high growth digital technology businesses, notes the announcement released by Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, that it is has signed a definitive agreement to acquire Endomagnetics Ltd. (ÔEndomagÕ). The acquisition, which is subject to regulatory approval as well as working capital and other customary closing adjustments values Endomag at approximately $310m.

https://www.londonstockexchange.com/news-article/GROW/hologic-inc-to-acquire-endomagnetics/16446345

Endomag is a medical technology company, based in Cambridge, devoted to improving the global standard of care in breast cancer. Its products include the Magseed¨ marker for magnetic tissue localisation before surgery, the Magtrace¨ lymphatic tracing injectable for breast cancer staging and the Sentimag¨ platform, which supports both localisation and lymphatic tracing.

Molten VCT first invested in Endomag in July 2018, with investment alongside the balance sheet of Molten Ventures plc (the parent company of the VCT Manager) and Molten VentureÕs separate EIS funds. Follow-on funding was provided to support EndomagÕs continued growth in 2020. The deal values Molten VCTÕs stake in Endomag modestly above its last released September 2023 interim holding value of £8.69million.

In its recent interims, published 14 December 2023, Molten noted ÒWe are hopeful that conditions will begin to improve in 2024 and that we may now be approaching a point in the cycle when excellent investment opportunities in the sectors in which your Company operates are available at attractive prices which can drive strong performance in the futureÓ

David Brock, Chairman of the VCT, commented:

ÒThis transaction demonstrates our ability through our VCT Manager to support innovative businesses as they scale and create value for our shareholders through the cycle.

These proceeds bolster the VCTs distributable reserves which are available for paying dividends and share buybacks. We will provide an update in respect of these anticipated proceeds at the time of the VCTs full year results which are due to be released towards the end of July 2024.Ò

-ENDS-

About Molten Ventures VCT

Molten Ventures VCT is a leading VCT developing and investing in disruptive, high growth technology companies through its VCT Manager Molten Ventures plc (LSE: GROW, Euronext Dublin: GRW).

Over the past six years, Molten Ventures plc has scaled its platform to enable access to some of the best deal flow across Europe. The participation of the VCT alongside co-branded Molten Ventures plc investment partners enable the VCT to obtain access to private technology company fundraisings that are rarely accessible to individual investors.

As at 30 September 2023, Molten Ventures VCT had a diverse portfolio and has invested over £45 million into 39 technology companies. We invest across four sectors: Enterprise Technology, Hardware and Deeptech, Consumer Technology, and Digital Health and Wellness, with highly experienced partners constantly looking for new opportunities in each. We look for high-growth companies operating in new markets, with aspirations for global expansion, strong IP, powerful technology, and strong management teams to deliver success. We also look for businesses with the potential to generate strong margins to ensure rapid, sustainable growth in substantial addressable markets.

The VCT therefore gives investors a rare opportunity to invest in private companies, in their high growth phase, that have the possibility to be breakthroughs in their field and become attractive candidates for acquisition, or IPO, with valuations from $50 million to $1 billion+.

For more information, go to https://investors.moltenventures.com/investor-relations/vct

1 May 2024